All In Biotech

Drug Trial Radar · NCT07424547

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

386

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Dec 2029

Study completion Apr 2030

Sponsor

Lead sponsor
Conjupro Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works. Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive SYS6043 by intravenous infusion once every 3 weeks (Q3W), with 21 days as one treatment cycle until the study doctor determines that study treatment should be stopped based on how well a participant is doing on treatment. * Have safety follow-up (SFU), and long-term follow-up. * Be followed until progression.

Conditions

  • Cancer
  • Solid Tumor Cancer
  • Advanced Metastatic Cancer
  • Prostate
  • Small Cell Lung Cancer
  • Ovarian Cancer
  • Breast Cancer

Interventions

  • SYS6043Drug

    Administered by intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a).Time frame: An average of 1 year.
  2. Incidence of Treatment-Emergent Adverse Events and dose-limiting toxicities (DLTs) [Safety and Tolerability] of SYS6043 during the study (Phase 1a)Time frame: An average 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • BRCR Global

    Plantation, Florida · Recruiting

  • Florida Clinical Trials Group

    Plantation, Florida · Recruiting

  • NEXT Oncology Austin

    Austin, Texas · Recruiting

  • NEXT Oncology San Antonio

    San Antonio, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.